[1] World Health Organization. Rabies vaccines: WHO position paper-April 2018. Geneva: WHO, 2018.
[2] The SAGE Working Group. Background paper: proposed revision of the policy on rabies vaccines and rabies immunoglobulins. Geneva: WHO, 2017.
[3] WHO. WHO Expert Consultation on Rabies, third report. Geneva: World Health Organization, 2018.
[4] Bureau of Disease Prevention and Control. 2020 General situation of legal infectious diseases in China. http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml. [2021-03-12]. (In Chinese)
[5] WHO. WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment. Geneva: WHO, 2002.
[6] Gogtay NJ, Munshi R, Ashwath Narayana DH, et al. Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: A phase 2/3, randomized, single-blind, noninferiority, controlled study. Clin Infect Dis, 2018; 66, 387−95. doi:  10.1093/cid/cix791
[7] Kansagra K, Parmar D, Mendiratta SK, et al. A phase 3, randomized, open-label, noninferiority trial evaluating anti-rabies monoclonal antibody cocktail (TwinrabTM) against human rabies immunoglobulin (HRIG). Clin Infect Dis, 2021; 73, e2722−8. doi:  10.1093/cid/ciaa779
[8] U. S. National Library of Medicine. A randomized phase II trial to compare the safety and neutralizing activity of CL184 in combination with rabies vaccine vs. HRIG or placebo in combination with rabies vaccine in healthy adult subjects. https://clinicaltrials.gov/ct2/show/results/NCT00656097?view=results. [2011-09-21].
[9] Comparison of SYN023 to human rabies immune globulin in post exposure prophylaxis of rabies-full text view-ClinicalTrials. gov. ClinicalTrials. gov Identifier: NCT03961555.
[10] A phase III clinical study to evaluate SYN023's efficacy and safety-full text view-clinicaltrials. gov. ClinicalTrials. gov Identifier: NCT04644484.
[11] Zhai LL, Wang H, Zhao W, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis, 2022; 46, 102267. doi:  10.1016/j.tmaid.2022.102267
[12] Smith JS, Yager PA, Baer GM. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ, 1973; 48, 535−41.
[13] National Medical Products Administration. Notice on printing and distributing six technical guiding principles such as the technical guiding principles for preclinical research of preventive vaccines. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20051014010101369.html. [2005-10-14]. (In Chinese)
[14] Bakker ABH, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity. Vaccine, 2008; 26, 5922−7. doi:  10.1016/j.vaccine.2008.08.050
[15] Gogtay N, Thatte U, Kshirsagar N, et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: A randomized, dose-escalation phase 1 study in adults. Vaccine, 2012; 30, 7315−20. doi:  10.1016/j.vaccine.2012.09.027
[16] Evaluation of new rabies vaccines for licensing C. 1.1 General considerations for the clinical assessment of rabies vaccines. WHO Expert Committee on Biological Standardization. Fifty-sixth report. WHO Technical Report Series, No. 941, 2007.
[17] WHO Publication. Rabies vaccines: WHO position paper—recommendations. Vaccine, 2010; 28, 7140−2. doi:  10.1016/j.vaccine.2010.08.082
[18] Center for Drug Evaluation, NMPA, Guidance. Notice on public solicitation of opinions on technical guidelines for clinical trials of new anti rabies virus monoclonal antibodies. http://www.cjpi.org.cn/zryyxxw/cfdazsjg/ypspzx/webinfo/2021/08/1622500688131908.htm. [2021-08-17]. (In Chinese)
[19] U. S. Food & Drug Administration. Rabies: developing monoclonal antibody cocktails for the passive immunization component of post-exposure prophylaxis guidance for industry.https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rabies-developing-monoclonal-antibody-cocktails-passive-immunization-component-post-exposure. [2021-07-28].
[20] Kostense S, Moore S, Companjen A, et al. Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples. Antimicrob Agents Chemother, 2012; 56, 3524−30. doi:  10.1128/AAC.06179-11